Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

The lucrative Alzheimer’s disease market could have a second player soon, posing strong competition to Biogen (BIIB) and its Japan-based partner Eisai’s Leqembi, approved last year in the United States to reduce the cognitive decline associated with early Alzheimer’s disease.On Jun 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly’s (LLY) Alzheimer's disease drug, donanemab.The committee said that data from clin ...